摘要
目的:观察二陈汤加味对急性加重期慢性阻塞性肺疾病(AECOPD)患者CXC趋化因子配体8(CXCL8)及其受体CXCR1/2,巨噬细胞炎性蛋白2(MIP-2)蛋白表达的影响,评价二陈汤加味对AECOPD患者抗炎的作用与机制。方法:选取符合纳入标准的AECOPD患者200例,随机分成观察组和对照组各100例。2组均在西药治疗的基础上,对照组给予急支糖浆,观察组给予二陈汤加味,疗程14 d。酶联免疫吸附测定(ELISA)检测患者血浆中巨噬细胞炎性蛋白2(MIP-2),CXCL8含量;蛋白免疫印迹法(Western blot)检测外周血单个核细胞(PBMCs)中CXCL8,CXCR1和CXCR2蛋白表达;免疫细胞化学染色检测PBMCs中CXCL8,CXCR1,CXCR2定位表达及阳性率。结果:治疗后观察组较同组治疗前血浆中CXCL8,MIP-2含量均显著减少(P<0.05),PBMCs中CXCL8,CXCR1,CXCR2蛋白表达均降低(P<0.05,P<0.01)。治疗后与对照组比较,观察组总有效率、肺FEV1均显著高于对照组(P<0.05),血浆MIP-2,CXCL8含量,CXCL8,CXCR1蛋白表达均显著低于对照组(P<0.05)。结论:二陈汤加味对COPD有抗炎作用。其机制可能与下调CXCL8,CXCR1,CXCR2表达,减少CXCL8,MIP-2的合成与释放,抑制炎细胞的过多渗出与趋化,从而减轻炎症反应有关。
Objective:To observe the clinical efficacy of modified Erchentang on CXC chemokine ligand receptors(CXCR1/2)and their ligands CXCL8,macrophage inflammatory protein-2(MIP-2)in patients of chronic obstructive pulmonary disease(AECOPD)at acute exacerbation stage,and assess the effect and mechanism of modified Erchentang on anti-inflammatory in patients of AECOPD.Method:This study was a multicenter,randomized single blind,controlled trial.The authors selected 200 cases in conformity to the standards of AECOPD.The AECOPD patients were randomly divided into modified Erchentang group and control group.In addition to the western medicine,modified Erchentang was also given to the modified Erchentang group,and Jizhitangjiang was given to the control group for 14 days.Each group was observed for the alleviation of the symptoms.Euzyme-linked immunosorbent assay(ELISA)was used to determine the levels of CXCL8 and MIP-2 in the patients’plasma of all groups before and after treatment.Western blot were used to detect the levels of CXCR1,CXCR2 and CXCL8 protein in peripheral blood mononuclear cells(PBMCs).Immunocytochemistry(ICC)method was used to detect the expressions of CXCL8,CXCR1 and CXCR2 protein in PBMCs.Result:The level of CXCL8 in plasma,and the expressions of CXCR1,CXCR2 and CXCL8 m RNA and protein in the modified Erchentang group were decreased significantly than those in the control group(P<0.05,P<0.01).Conclusion:Modified Erchentang has an anti-inflammatory effect on AECOPD.Its mechanism may be related to the down-regulation of the expressions of CXCL8,CXCR1 and CXCR2,the reduction of synthesis and release of CXCL8 and MIP-2,the inhibition of the chemotaxis and activity of inflammatory cells,and the prevention of inflammation progress.
作者
尚立芝
季书
李耀洋
毛梦迪
王国强
石龙涛
张光远
徐莉莉
谢文英
SHANG Li-zhi;JI Shu;LI Yao-yang;MAO Meng-di;WANG Guo-qiang;SHI Long-tao;ZHANG Guang-yuan;XU Li-li;XIE Wen-ying(Henan University of Chinese Medicine,Zhengzhou 450046,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2019年第24期1-8,共8页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家自然科学基金面上项目(81573881)
河南省高等学校重点科研项目(15A360030)
河南省科重点技攻关项目(182102311163)
河南省教育科学“十三五”规划一般课题([2019]-JKGHYB-0101,[2019]-JKGHYB-0114)
国家级大学生创新创业训练计划项目(S201810471013,S201910471010)
河南中医药大学生创新学习项目(CXXM[2017]0252,CXXM[2019]0001)
关键词
慢性阻塞性肺疾病
二陈汤
外周血单个核细胞
炎症
趋化因子
chronic obstructive pulmonary disease(COPD)
Erchentang
peripheral blood mononuclear cells(PBMCs)
inflammation
chemokine
